Aurinia Pharmaceuticals
AUPH
64 hedge funds and large institutions have $113M invested in Aurinia Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 14 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
4% more capital invested
Capital invested by funds: $108M → $113M (+$4.76M)
2.54% less ownership
Funds ownership: 28.38% → 25.84% (-2.5%)
6% less funds holding
Funds holding: 68 → 64 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
79% less call options, than puts
Call options by funds: $595K | Put options by funds: $2.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.74M |
| 2 |
Morgan Stanley
New York
|
+$1.28M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.24M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$1.07M |
| 5 |
Goldman Sachs
New York
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.27M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.43M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.27M |
| 4 |
AIC
AWM Investment Company
New York
|
-$1.61M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.13M |
AUPH Hedge Fund Activity: Q1 2018 in Review
64 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2018, worth a combined $113M — up 4.4% from $108M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AUPH and 10 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 19 added.
The largest buyer was BlackRock, adding an estimated $1.74M. The largest seller was OrbiMed, cutting an estimated $6.27M.
- 64 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2018, down from 68 in Q4 2017.
- Funds reported $113M of Aurinia Pharmaceuticals stock for Q1 2018, up 4.4% quarter-over-quarter.
- 10 funds opened new Aurinia Pharmaceuticals positions in Q1 2018 and 14 closed out, a net change of -4 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2018 was BlackRock, an estimated $1.74M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $6.27M sold.
Based on aggregated 13F filings for Q1 2018.